Shots: Tum Bio to receive $1M upfront, up to $73M milestones and royalties on sales. Chiesi to get worldwide development and commercialization rights & will be responsible for its clinical trials The focus of the agreement is to develop and commercialize NCE401, a TGF-beta inhibitor in the fields of respiratory diseases NCE401 is a preclinical […]Read More
